Drug intelligence / Profile preview

Inhibinol

Development stage: Unknown
Lead developer: Skymount Medical
Administration: Oral

Overview

Inhibinol is a patent-pending nutraceutical supplement developed by Skymount Medical in partnership with Louisiana State University (LSU). It was formulated using the DeepDrug™ artificial intelligence platform to identify a specific combination of four nutraceuticals that, when combined with essential vitamins and minerals, support the immune system, cardiovascular health, and antioxidant functions. Key ingredients include ginseng, chamomile, vitamin D, zinc, and biotin. The product is designed to correct micronutrient imbalances, neutralize free radicals, and reduce inflammation following physical exertion. It is marketed as one of the first AI-recommended dietary supplements and is available as a consumer health product in the United States.

Brand names: Inhibinol
Other names: Inhibinol™

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Inhibinol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibinol.

Explore the full profile